| Author |
N |
Therapy Regimen |
EGFR analysis* |
Publication
status |
| Cutsem et al. [10] |
1,198 |
E: FOLFIRI + cetuximab |
Yes |
Published |
| C: FOLFIRI |
| Borner et al. [18] |
74 |
E: XELOX + cetuximab |
No |
Published |
| C: XELOX |
| Bokemeyer et al. [12]
|
337 |
E: FOLFOX-4 + cetuximab |
Yes |
Published |
| C: FOLFOX-4 |
| Douillard et al. [11] |
1,183 |
E: FOLFOX-4 + panitumumab |
Yes |
Published |
| C: FOLFOX-4 |
| Maughan et al. [21] |
1,630 |
E: OX-based therapy + cetuximab |
Yes |
Published |
| C: OX-based therapy |
| Tveit et al. [19] |
566 |
E: FLOX + cetuximab |
Yes |
Abstract |
| C: FLOX |
FOLFIRI: Irinotecan, Leucovorin and Fluorouracil; XELOX: Oxaliplatin and Capecitabine; FOLFOX-4: Oxaliplatin, Leucovorin, and Fluorouracil; BSC: Best Supportive Care;
OX: Oxaliplatin; FLOX: Oxaliplatin, Leucovorin, and Fluorouracil
*Whether this trial evaluated the efficacy of anti-EGFR antibody on the status of KRAS mutant. |
